/IMCR
IMCR Stock - Immunocore Holdings plc
Healthcare|BiotechnologyNASDAQ
$36.01+0.31%
+$0.11 (+0.31%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+33.3%upside
Target: $48.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.65 – $36.37
TARGET (TP)$48.00
STOP LOSS$33.13
RISK/REWARD1:4.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$40.72
52W Low$23.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $247.77M | $249.43M | $144.23M | $36.48M | $30.11M |
| Gross Profit | $239.38M | $248.39M | $138.94M | $36.48M | $-44,695,000 |
| Gross Margin | 96.6% | 99.6% | 96.3% | 100.0% | -148.4% |
| Operating Income | $-56,280,019 | $-59,649,000 | $-42,773,891 | $-174,587,000 | $-86,193,000 |
| Net Income | $-40,805,230 | $-55,287,000 | $-43,464,620 | $-180,029,000 | $-74,093,000 |
| Net Margin | -16.5% | -22.2% | -30.1% | -493.4% | -246.0% |
| EPS | $-1.02 | $-1.13 | $-0.95 | $-3.13 | $-2.33 |
Company Overview
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
67%
Hold / Neutral
5
28%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
12 Bullish6 Neutral/Bearish
Price Targets
$63
Average Target
↑ 74.3% Upside
Now
$16
Low
$63
Average
$85
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 31st 2025 | Wells Fargo | Initiation | Overweight | $60 |
| September 18th 2025 | Guggenheim | Resumed | Neutral | - |
| August 25th 2025 | Jefferies | Resumed | Buy | $48 |
| May 27th 2025 | Deutsche Bank | Initiation | Buy | $65 |
| December 13th 2024 | Morgan Stanley | Downgrade | Equal Weight | $35← $74 |
| November 11th 2024 | Mizuho | Downgrade | Neutral | $38← $72 |
| October 24th 2024 | UBS | Initiation | Sell | $24 |
| October 7th 2024 | Guggenheim | Downgrade | Neutral | - |
| April 29th 2024 | Leerink Partners | Initiation | Outperform | $74 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $60 |
| November 2nd 2023 | Cantor Fitzgerald | Initiation | Overweight | - |
| October 31st 2023 | Robert W. Baird | Initiation | Outperform | $84 |
| September 13th 2023 | Needham | Initiation | Buy | $75 |
| September 13th 2023 | JP Morgan | Upgrade | Overweight | $22← $9 |
| August 16th 2023 | CapitalOne | Initiation | Overweight | $84 |
Earnings History & Surprises
IMCRBeat Rate
56%
Last 18 quarters
Avg Surprise
-10253.9%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$0.02
Q4 2025
EPS Surprise History
Q1 24
-42.9%
$-0.40vs$-0.28
Q2 24
-48.5%
$-0.49vs$-0.33
Q3 24
+48.9%
$-0.23vs$-0.45
Q4 24
+148.6%
$0.17vs$-0.35
Q1 25
-51.6%
$-0.47vs$-0.31
Q2 25
+128.6%
$0.10vs$-0.35
Q3 25
+4.8%
$-0.20vs$-0.21
Q4 25
+105.2%
$0.02vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.30 | $0.02 | +105.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.35 | $0.10 | +128.6% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.31 | $-0.47 | -51.6% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.35 | $0.17 | +148.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.45 | $-0.23 | +48.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.33 | $-0.49 | -48.5% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.28 | $-0.40 | -42.9% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.32 | $0.04 | +112.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.30 | $-0.43 | -43.3% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.00 | $-0.63 | -185194.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.26 | $0.14 | +153.8% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.72 | $-0.17 | +76.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-1.07 | $-0.48 | +55.1% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-1.08 | $-1.21 | -12.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.85 | $-0.93 | -9.4% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.95 | $-1.04 | -9.5% | ✗ MISS |
Latest News
Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Raises Price Target to $36
📈 PositiveBenzinga•Nov 10, 2025, 05:54 PM
Immunocore Releases Phase 1 Data For IMC-I109V Showing That It Has A Manageable Safety Profile And Demonstrates Antiviral Activity, Including Reductions In HBsAg Levels, Consistent With Its Mechanism Of Action
📈 PositiveBenzinga•Nov 7, 2025, 01:10 PM
Immunocore Hldgs Q3 Sales $103.693M Beat $100.186M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:28 PM
Wells Fargo Initiates Coverage On Immunocore Holdings with Overweight Rating, Announces Price Target of $60
📈 PositiveBenzinga•Oct 31, 2025, 09:02 PM
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 05:36 PM
Guggenheim Assumes Immunocore Holdings at Neutral
➖ NeutralBenzinga•Sep 18, 2025, 01:26 PM
Frequently Asked Questions about IMCR
What is IMCR's current stock price?
Immunocore Holdings plc (IMCR) is currently trading at $36.01 per share. The stock has moved +0.31% today.
What is the analyst price target for IMCR?
The average analyst price target for IMCR is $48.00, based on 1 analyst.
What sector is Immunocore Holdings plc in?
Immunocore Holdings plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMCR's market cap?
Immunocore Holdings plc has a market capitalization of $1.82 billion, making it a small-cap company.
Does IMCR pay dividends?
No, Immunocore Holdings plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MNKD
MannKind Corporation
$5.84
Mkt Cap: $1.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
XERS
Xeris Biopharma Holdings, Inc.
$7.34
Mkt Cap: $1.2B
Explore stocks similar to IMCR for comparison